Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced the launch of its optical coherence tomography (OCT)-Tissue Surveillance Registry—a database designed to collect thousands of images from surgical...
Profound Medical (NASDAQ: PROF; TSX: PRN) today announced that it has entered into a consulting agreement with Leonard Wheeler—former NFL player, entrepreneur, author, corporate consultant, co-executive director of the...
Defence Therapeutics (CSE: DTC; OTCQB: DTCFF; FSE: DTC) announced that it has opened its first U.S.-based laboratory in the Boston-Cambridge area. According to Defence, the new laboratory will allow the company to...
atai Life Sciences (NASDAQ: ATAI) and closely held Beckley Psytech announced a definitive agreement to combine in an all-share transaction subject to Phase 2b success criteria of BPl-003 in patients with treatment...
Genflow Biosciences (LSE:GENF; OTCQB:GENFF) has announced the signing of a master service agreement (MSA) with closely held CER Groupe—a long-standing partner—to strengthen long-term research and development (R&D)...
NeoGenomics (NASDAQ: NEO) has announced that it will debut its PanTracer Family genomic profiling tests for advanced solid tumors at the 2025 American Society of Clinical Oncology (ASCO) in Chicago May 30—June 3, 2025...
Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced that it has entered into a development support agreement with Intermountain Health, creating the framework for the two organizations to partner on a...
Quoin Pharmaceuticals (NASDAQ: QNRX) announced that the FDA has provided clearance to initiate a second Netherton Syndrome (NS) clinical pivotal study—CL-QRX003-002, for Quoin’s lead product QRX003. According to Quoin...
NorthStrive Biosciences (NASDAQ:ELAB) announced the completion of a Phase I strategic research and literature synthesis for EL-22 (formerly BLS-M22), its first-in-class oral myostatin-engineered probiotic targeting...
Zura Bio (NASDAQ:ZURA) announced that it has launched a global Phase 2 study—TibuSHIELD—to evaluate tibulizumab in 180 adults with moderate to severe hidradenitis suppurativa (HS) across Canada, the U.S. and Europe...